Crohn’s disease (CD) is one of the major subtypes of inflammatory bowel disease (IBD). It can affect any part of the gastrointestinal tract from the mouth to the rectum, most commonly involving the terminal ileum and adjacent colon. Typical histological features include mucosal erosion, transmural inflammation, granuloma formation, and secondary fibrosis and fistula development. Clinically, it often presents with chronic abdominal pain, diarrhea, weight loss, anemia, and nutritional deficiencies, and may be accompanied by extraintestinal manifestations involving multiple systems, such as immune-related lesions in joints, skin, and eyes.

The pathogenesis of CD remains incompletely understood but is widely recognized to involve genetic susceptibility, gut microbiota dysbiosis, and immune dysfunction. Genetically, more than 200 risk loci have been identified, with mutations in genes such as NOD2 and ATG16L1 impairing intestinal barrier function and bacterial recognition. Gut microbiota imbalance—characterized by enrichment of Enterobacteriaceae and reduced mucosal microbial diversity—triggers inflammation through mucosal penetration and metabolic disruption. Immune abnormalities primarily manifest as aberrant myeloid-stromal cell crosstalk, excessive activation of TH1/TH17 cells, and massive release of proinflammatory cytokines (TNF, IL-17, OSM, etc.), ultimately leading to chronic intestinal inflammation and tissue damage.

Figure 1. Crohn’s disease-associated genetic mutations, intestinal abnormalities and pathobionts.

Core Targets and Mechanisms in Crohn’s Disease Research

The pathological network of CD involves multiple pathways, including intestinal barrier function, immune regulation, and microbial metabolism. The following key targets provide critical directions for disease intervention:

Recent Breakthroughs in Crohn’s Disease Research

In recent years, technologies such as single-cell sequencing and multi-omics have led to several groundbreaking discoveries in CD research:

1. Identification of a specific LND epithelial cell subset highly expressing LCN2, NOS2, and DUOX2. This subset expands significantly in active CD, drives mucosal inflammation by recruiting immune cells, and its proportion can predict response to anti-TNF therapy.
2. Confirmation that aberrant myeloid-stromal cell crosstalk is central to perianal fistula pathogenesis, with CHI3L1+ fibroblasts co-expressing fibrotic and destructive gene signatures; the AP-1 transcription factor family regulates key inflammatory genes.
3. Discovery of pathobionts in the gut microbiota (e.g., adherent-invasive Escherichia coli [AIEC] and Ruminococcus species) that promote inflammation by degrading the mucus layer and cross-feeding metabolites, providing a basis for microbiota-targeted therapies.
4. Evidence of ethnic differences in CD pathogenesis: African-descended patients show abnormal myeloid cell differentiation, elevated CHI3L1 and OSM expression, higher fistula incidence, and more severe disease.

Core Challenges in Crohn’s Disease Research

Crohn’s disease research continues to face several unresolved challenges:

1. At the etiological level, the “cause-versus-consequence” paradox of gut microbiota dysbiosis remains unsolved—it is unclear whether dysbiosis triggers disease or results from inflammation. High inter-individual variability and the lack of universal “disease-specific” microbial markers complicate the issue.
2. In precision diagnostics and treatment, validated prognostic biomarkers are lacking, making it difficult to predict disease progression (e.g., strictures or fistulas) or drug response (e.g., anti-TNF failure risk). Diagnosis relies on nonspecific inflammatory markers (CRP, fecal calprotectin), small bowel lesions are easily missed, and global diagnostic and management protocols lack standardization, particularly for complications such as intestinal fibrosis or cutaneous manifestations.
3. Therapeutically, current options (biologics, surgery) offer limited long-term efficacy. Median duration of anti-TNF response is only 2–3 years. Fecal microbiota transplantation (FMT) shows promise but suffers from inconsistent results due to small sample sizes and methodological variability. Head-to-head trial data for newer agents (e.g., IL-23 inhibitors) are insufficient to establish optimal treatment sequencing.

Additionally, research has historically focused on European and North American populations, leaving data gaps for regions with rising incidence (Asia, Africa) and failing to capture ethnic/regional disease heterogeneity. Interactions between environmental triggers (diet, timing of microbial exposure) and genetic susceptibility also remain poorly defined. These challenges underscore the need for multi-target, multi-dimensional research tools—abinScience provides targeted reagents for core pathways to help overcome these bottlenecks.

Latest abinScience Recombinant Proteins and Antibodies for Crohn’s Disease Research

Below is the latest selection of abinScience recombinant proteins, antibodies, and kits relevant to Crohn’s disease research. Catalog numbers link directly to product pages.

Recombinant Proteins

Antibodies

Kits